Bold opening: Researchers are finally connecting thousands of genetic clues to MS, paving the way for real breakthroughs in how the disease starts and how people live with it. But here’s where it gets controversial: can linking many tiny genetic changes actually translate into precise, life-changing treatments? The answer is moving in that direction, and this rewrite explains how.
Australian scientists are taking a major step toward understanding multiple sclerosis (MS) by studying more than 100 genetic risk factors together. This collaborative effort, led by Dr. Hamish King of WEHI and funded by MS Australia’s latest 2.8 million dollar research grant, fills a long-standing gap in MS genetics. Over the past twenty years, large genetic studies have identified hundreds of small DNA differences tied to higher MS risk. Most of these changes don’t directly alter genes. Instead, they influence when and how genes are turned on in immune cells, making it hard to see exactly how they contribute to the disease.
Until now, understanding how these MS-linked risk factors work together to drive disease has been a major challenge for researchers. Dr. King’s team will introduce and test these genetic risk factors in human immune cells, measuring how they alter gene activity and immune behavior both individually and in combination. By mapping networks of risk genes and their interactions, the researchers aim to unlock more precise treatments and, ultimately, better long-term outcomes for people living with MS.
“For more than 20 years, we’ve known there are many genetic markers linked to MS risk, but we haven’t been able to fully explain how they change immune cell behavior,” Dr. King said. “MS can arise from many small genetic differences acting together, and this platform will let us study those changes collectively and connect them to the specific genes and pathways they affect.”
MS is an immune-mediated condition in which the body mistakenly attacks the brain and spinal cord, damaging myelin—the protective coating around nerve fibers. This damage can affect mobility, vision, thinking, and energy levels. In 2025, more than 37,700 Australians were living with MS, up 77.4% since 2010, and the total economic burden reached $3 billion in 2024. As the number of people with MS rises, accelerating research across the full spectrum of the disease becomes increasingly urgent.
MS Australia’s Head of Research, Dr. Tennille Luker, emphasizes that projects like Dr. King’s help close a critical gap between genetic discovery and real-world impact. “Identifying risk was only the beginning. Understanding how those genetic changes actually drive disease allows us to change its trajectory.” She adds that, alongside this genetic work, funding goes toward slowing progression, managing symptoms, and improving quality of life, thereby strengthening today’s response while laying the groundwork for prevention and cures.
Beyond core funding, the Browne Family’s generosity supports a Postdoctoral Fellowship, awarded to Dr. James Hilton at the University of Melbourne to develop new compounds to protect nerve cells in progressive MS. Over more than two decades, MS Australia has invested more than $60 million in MS research. CEO Rohan Greenland notes that sustained national investment is essential to delivering real progress for people living with MS: research represents hope and the possibility of better treatments and prevention.
The 2026 research grants will be formally launched at Parliament House in Canberra on March 4, during MS Australia’s Advancing MS Research in Australia event. Speakers include Dr. Monique Ryan MP and Ms. Renee Coffey MP, who will highlight the importance of maintaining national support for MS research.
Featured projects include:
- Sensory shoe insoles to improve balance in MS, led by Associate Professor Anna Hatton at The University of Queensland. The team is testing “Vibrotexture” insoles that enhance foot sensation to improve upright stability and reduce fall risk, aiming for a clinically ready product that can be used worldwide and inform future treatments focused on foot sensation.
- Protecting brain blood flow to slow MS progression, led by Professor Kaylene Young at the Menzies Institute for Medical Research, University of Tasmania. Using stem cell models, the team will explore how genetic differences affect brain blood flow, inflammation, and nerve survival with the goal of identifying drug targets that preserve myelin and slow disability.
- Investigating how common viruses may trigger MS, led by Mr. Alex Eisner at the Florey Institute and University of Melbourne. The project examines Epstein-Barr virus and other herpesviruses in relation to MS risk, antibody responses, and epigenetic changes, aiming to clarify molecular mechanisms behind viral influence on MS and inform new strategies.
- Exploring copper disruption as a link among MS risk factors, led by Dr. Brittney Lins at Curtin University. The research asks whether brain copper imbalance connects factors like Epstein-Barr infection, vitamin D deficiency, and gut health, potentially making myelin more vulnerable to inflammation and guiding new prevention and treatment approaches.
If you’d like, I can tailor this rewrite for a specific audience (general readers, clinical audience, or students) or adjust the emphasis on certain projects. Which angle would you prefer?
